Acute myelogenous leukemia and its microenvironment: A Molecular conversation

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 200-206

  Ghiaur, Gabriel ^a   Wroblewski, Mark ^b   Loges, Sonja ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; BETA1 INTEGRIN; BEVACIZUMAB; BGB 324; CD18 ANTIGEN; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYTARABINE; DICER; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH ARREST SPECIFIC PROTEIN 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LENALIDOMIDE; MITOXANTRONE; POMALIDOMIDE; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLOOD VESSEL PARAMETERS; BONE MARROW; BONE MARROW STROMA CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CELL COUNT; CELL EXPANSION; CELL INTERACTION; CELL STIMULATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE INACTIVATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA RELAPSE; MACROPHAGE FUNCTION; MALIGNANT TRANSFORMATION; MARROW VASCULAR DENSITY; MESENCHYMAL STROMA CELL; MESENCHYME CELL; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OSTEOBLAST; OSTEOPROGENITOR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN SECRETION; STEM CELL NICHE; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIUM; ANIMAL; CELL COMMUNICATION; LEUKEMIA, MYELOID, ACUTE; STEM CELL;

ANIMALS; BONE MARROW; CELL COMMUNICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84937434287     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.03.003     Document Type: Review

References (58)

1. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
2. Gerber J.M., Smith B.D., Ngwang B., et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012, 119:3571-3577.
3. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
4. Ghiaur G., Gerber J., Jones R.J. Concise review: cancer stem cells and minimal residual disease. Stem cells 2012, 30:89-93.
5. Scadden D.T. Nice neighborhood: emerging concepts of the stem cell niche. Cell 2014, 157:41-50.
6. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
7. Ninomiya M., Abe A., Katsumi A., et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007, 21:136-142.
8. Kremer K.N., Dudakovic A., McGee-Lawrence M.E., et al. Osteoblasts protect AML cells from SDF-1-induced apoptosis. J Cell Biochem 2014, 115:1128-1137.
9. Krevvata M., Silva B.C., Manavalan J.S., et al. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood 2014, 124:2834-2846.
10. Schepers K., Pietras E.M., Reynaud D., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013, 13:285-299.
11. Hanoun M., Zhang D., Mizoguchi T., et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell 2014, 15:365-375.
12. Krause D.S., Fulzele K., Catic A., et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 2013, 19:1513-1517.
13. Kode A., Manavalan J.S., Mosialou I., et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 2014, 506:240-244.
14. Raaijmakers M.H., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
15. Padro T., Ruiz S., Bieker R., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95:2637-2644.
16. Kini A.R., Peterson L.A., Tallman M.S., Lingen M.W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001, 97:3919-3924.
17. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
18. Rabitsch W., Sperr W.R., Lechner K., et al. Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma 2004, 45:1369-1373.
19. Kini A.R., Kay N.E., Peterson L.C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000, 14:1414-1418.
20. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94:3717-3721.
21. Karp J.E., Gojo I., Pili R., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004, 10:3577-3585.
22. Cogle C.R., Goldman D.C., Madlambayan G.J., et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia 2014, 28:1978-1987.
23. Hatfield K., Oyan A.M., Ersvaer E., et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 2009, 144:53-68.
24. Loges S., Heil G., Bruweleit M., et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005, 23:1109-1117.
25. Sozer S., Fiel M.I., Schiano T., Xu M., Mascarenhas J., Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009, 113:5246-5249.
26. Ben-Batalla I., Schultze A., Wroblewski M., et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 2013, 122:2443-2452.
27. Whitman S.P., Kohlschmidt J., Maharry K., et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia 2014, 28:1252-1258.
28. Park I.K., Mishra A., Chandler J., Whitman S.P., Marcucci G., Caligiuri M.A. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 2013, 121:2064-2073.
29. Lee-Sherick A.B., Eisenman K.M., Sather S., et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene 2013, 32:5359-5368.
30. Kariolis M.S., Miao Y.R., Jones D.S., et al. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Cehm Biol 2014, 10(11):977-983.
31. Bendall L.J., Kortlepel K., Gottlieb D.J. Human acute myeloid leukemia cells bind to bone marrow stroma via a combination of beta-1 and beta-2 integrin mechanisms. Blood 1993, 82:3125-3132.
32. Ryningen A., Wergeland L., Glenjen N., Gjertsen B.T., Bruserud O. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res 2005, 29:185-196.
33. Hatfield K.J., Reikvam H., Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010, 17:4448-4461.
34. Blau O., Baldus C.D., Hofmann W.K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118:5583-5592.
35. Kobune M., Iyama S., Kikuchi S., et al. Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms. Blood Cancer J 2012, 2:e87.
36. Jacamo R., Chen Y., Wang Z., et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood 2014, 123:2691-2702.
37. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
38. Despeaux M., Labat E., Gadelorge M., et al. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia 2011, 25:1789-1793.
39. Walkley C.R., Olsen G.H., Dworkin S., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129:1097-1110.
40. Ghiaur G., Yegnasubramanian S., Perkins B., Gucwa J.L., Gerber J.M., Jones R.J. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. Proc Natl Acad Sci U S A 2013, 110:16121-16126.
41. Walkley C.R., Shea J.M., Sims N.A., Purton L.E., Orkin S.H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007, 129:1081-1095.
42. Chow A., Lucas D., Hidalgo A., et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011, 208:261-271.
43. Greenbaum A., Hsu Y.M., Day R.B., et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013, 495:227-230.
44. Mussai F., De Santo C., Abu-Dayyeh I., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 2013, 122:749-758.
45. Majeti R., Chao M.P., Alizadeh A.A., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
46. Lukasova E., Koristek Z., Klabusay M., et al. Granulocyte maturation determines ability to release chromatin NETs and loss of DNA damage response; these properties are absent in immature AML granulocytes. Biochim Biophys Acta 2013, 1833:767-779.
47. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
48. Lo-Coco F., Avvisati G., Vignetti M., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
49. Schlenk R.F., Dohner K., Kneba M., et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009, 94:54-60.
50. Su M, Jones RJ, Ghiaur G. Bone marrow (BM) stromal expression of cytochrome P450 (CYP) enzymes protects acute myeloid leukemia (AML) from all-trans retinoic acid (atRA). Amercian Society of Hematology Annual Meeting 2013. New Orleans, LA; p 1449.
51. Alonso S, Su M, Jones RJ, Ghiaur G. The stem cell niche detoxifies chemotherapy and protects malignant hematopoietic cells via expression of cytochrome P450 enzymes. Amercian Association of Cancer Research Annual Meeting 2014. San Diego, CA; 2014.
52. Boyd A.L., Campbell C.J., Hopkins C.I., et al. Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. J Exp Med 2014, 211:1925-1935.
53. Tavor S., Petit I., Porozov S., Avigdor A., Dar A., Leider-Trejo L., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004, 64:2817-2824.
54. Uy G.L., Rettig M.P., Motabi I.H., et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012, 119:3917-3924.
55. Rombouts E.J., Pavic B., Lowenberg B., Ploemacher R.E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104:550-557.
56. Wnuk-Lipinska K, Tiron C, Gausdal G, et al. BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies. Amercian Association for Cancer Research Annual Meeting 2014. San Diego, CA; 2014.
57. Wellbrock J, Koehler JM, Wagner K, et al. Expression of Hedgehog pathway mediator Gli2 represents a clinically negative prognostic marker in acute myeloid leukemia and its inhibitor GANT61 exerts anti-leukemic effects in vitro. Amercian Association of Cancer Research Annual Meeting 2013. New Orleans, LA; 2013.
58. Boyd A.L., Salci K.R., Shapovalova Z., McIntyre B.A., Bhatia M. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors. Exp Hematol 2013, 41:858-869.